JASON BOUDREAUX: Open Payments
NPI 1760757074 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,032 in 52 payments from 13 companies in 2025. Trend: 2023 $1,264 · 2024 $1,032 · 2025 $1,032
Food & beverage: $1,031Education: $1
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $206 |
| Vanda Pharmaceuticals Inc. | 8 | $173 |
| ABBVIE INC. | 9 | $146 |
| Alkermes, Inc. | 6 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $105 |
| Corium, LLC | 4 | $64 |
| E.R. Squibb & Sons, L.L.C. | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lundbeck LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: INGREZZA, FANAPT, VRAYLAR, ARISTADA, CAPLYTA, Azstarys, COBENFY, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
